Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL
The venetoclax, obinutuzumab combination met the primary endpoint of the late-stage trial called CLL14, which was investigator-assessed progression-free survival (PFS). The combination therapy, which was administered for a